This study is being offerred to patients that have acute myelogenous leukemia (AML) which is a cancer of the blood and these patients are going to have a stem cell transplant. This study is looking to determine how accurate two different laboratory tests are at detecting residual, or small numbers of cancer cells in the body before and after stem cell transplant, as well as whether or not results of these two tests show how well a recipient might do after transplant.
This study if for patients that have a blood disease and it's been determined that the best option for treating that blood disease is a cord blood transplant. Cord blood (CB) is blood that is taken from the umbilical cord and placenta of healthy newborn babies after childbirth. The cord blood collected from a newborn baby is called a cord blood unit. The United States Food and Drug Administration (FDA) considers cord blood to be a biological drug. These are considered “investigational” products. This study will evaluate the safety of administration of the investigational cord blood units by carefully documenting all infusion-related problems.
This study will collect and analyze recipient blood and urine and donor tissue of adult kidney transplant recipients who are undergoing a renal transplant biopsy as part of their standard of care follow-up. The blood, urine, and tissue will be processed and analyzed for genomic variants and proteomic biomarkers that have been associated with immunosuppressant related adverse events and clinical outcomes, including graft dysfunction and graft loss. These patients will be followed clinically per the normal standard of care. The clinical outcomes of each patient are tracked using a transplant-specific clinical database (Velos and EPIC). The genomic polymorphisms and urinary proteomic biomarkers of each patient will be collected through blood, urine, and tissue samples and recorded and linked to the clinical outcomes data. Following this, the linked databases will be de-identified to PHI and analyzed to determine which genomic polymorphisms and/or proteomic biomarkers are most associated with deleterious clinical outcomes (graft dysfunction and graft loss).
This is a prospective, multi-center, randomized, placebo-controlled clinical trial in which 400 primary heart
transplant recipients with a PRA of <10% will be randomized (1:1) to conventional immunosuppression
(tacrolimus, MMF and steroid taper) versus induction therapy with anti-CD20 mAb (1gm IV on day 0 and day 12
post-transplant) plus conventional immunosuppression (tacrolimus, MMF, and steroid taper).
Up to 40 patients will be completing this study. This study will only be conducted at MUSC. All participants will be randomized, into two groups, one that takes Valganciclovir for 200 days after transplant and one that takes Valganciclovir for 100 days after transplant with Cytogam given at 90 days, 120 days, and 180 days post-transplant. The study will follow patients for 24 months after transplant.
The main purpose of this study in Phase I is to determine the maximum tolerated dose of carfilzomib when added to standard melphalan conditioning for AHSCT in relapsed Multiple Myeloma and in the Phase II portion of the study the purpose is to evaluate the anti-myeloma activity and the toxicity of carfilzomib + high dose melphalan conditioning in relapsed Multiple Myeloma
This study is a retrospective chart review that will be conducted by the primary investigator aimed at determining the association between adverse drug reactions and medication errors with negative outcomes. These negative outcomes are defined as the occurrence of acute or chronic rejection. Data will be collected by chart review of patients meeting the inclusion and exclusion criteria between March 2009 and July 2011. Charts will be reviewed for information as outlined by the data monitoring form. Statistical analysis will be performed according to the appropriate statistical test. Estimated timeline following IRB approval is data collection from September through November and final manuscript draft and submission May.
The main purpose of this study is to evaluate CNDO-109 Activated Allogeneic Natural Killer Cells (NK Cells) and how participants with Acute Myeloid Leukemia (AML) respond when given this therapy. The primary objective of this study is to define the maximum tolerated dose (MTD), or the maximum tested dose of CNDO-109-Activated Allogeneic Natural Killer cells infused (given) after preparative chemotherapy. NK cells are a type of blood cell in your immune system that attack cancer cells.